Cargando…

Myositis as a rare complication after tocilizumab treatment

Detalles Bibliográficos
Autores principales:	Quesada-Masachs, Estefania, Caballero, Consuelo Modesto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191689/ http://dx.doi.org/10.1186/1546-0096-12-S1-P345

Ejemplares similares

Imaging of refractory chronic recurrent multifocal osteomyelitis succesfully treated with etanercept and methotrexate
por: Quesada-Masachs, Estefania, et al.
Publicado: (2014)

PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis
por: Quesada-Masachs, E, et al.
Publicado: (2013)

12. When is inflammatory myositis not inflammatory myositis?
por: McShane, Annmarie, et al.
Publicado: (2019)

2. Pregnancy and myositis
por: Jain, Nibha, et al.
Publicado: (2019)

Juvenile dermatomyositis (JDM) sine myositis
por: Schuetz, C, et al.
Publicado: (2011)

8. Myositis as an idiosyncratic drug reaction to leflunomide
por: Darren, Angeline, et al.
Publicado: (2019)

Orbital myositis: a report of 3 pediatric cases
por: Chédeville, Gaëlle, et al.
Publicado: (2012)

10. Warning: statin-induced autoimmune necrotising myositis
por: Jasim, Muhamad, et al.
Publicado: (2019)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
por: Sawhney, Sujata, et al.
Publicado: (2012)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Juvenile overlap myositis: retrospective study about 20 cases
por: Piccolo, Vanessa Remy, et al.
Publicado: (2014)

Inflammatory myositis in the pediatric rheumatology clinical practice – a case series
por: Gomes, S Melo, et al.
Publicado: (2011)

Tocilizumab for the treatment of refractory pediatric mixed connective tissue disease (MCTD), in two patients
por: Cabrera, Natalia, et al.
Publicado: (2014)

Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies
por: Mehta, P, et al.
Publicado: (2010)

PReS-FINAL-2251: Influenza myositis outbreaks: clinical and laboratory findings
por: Cardin, SP, et al.
Publicado: (2013)

Acute viral myositis – particular aspects in the epidemiology of respiratory virus diseases in 2013
por: Bodea-Alucăi, Andreea, et al.
Publicado: (2013)

Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
por: Galeotti, C, et al.
Publicado: (2011)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

Tocilizumab for refractory Castleman’s disease with paraneoplastic pemphigus and Behçet’s disease
por: Vargas, Ana Beatriz, et al.
Publicado: (2012)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Isolated anti-Ku antibody in scleroderma-myositis overlap syndrome: the histo-pathological patern
por: Azanmene, Bernard, et al.
Publicado: (2012)

Mosaic tetrasomy 9p: a mendelian interferonopathy associated with pediatric-onset overlap myositis
por: Frémond, M-L, et al.
Publicado: (2015)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

P13 Calciphylaxis as a rare skin manifestation in a patient with an inflammatory myositis
por: Tabassum, Syeda, et al.
Publicado: (2023)

Rare and frequent postoperative complications after combined pneumonectomy for nonsmall-cell lung cancer
por: Lyas, N, et al.
Publicado: (2013)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

PReS-FINAL-2198: Insufficient efficacy of tocilizumab therapy in children with Castleman's disease
por: Kozlova, A, et al.
Publicado: (2013)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Induced myelopathy after long-term anti-tumor necrosis factor alpha treatment
por: Modesto, C, et al.
Publicado: (2011)

PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
por: Mihailova, D, et al.
Publicado: (2013)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
por: Russo, R, et al.
Publicado: (2011)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0lfcm06ad9ehugrnqqrnokcilh